PDCD1 and urinary bladder carcinoma: However, of the five anti‐PD‐1/PD‐L1 antibody drugs approved for cancer immunotherapy, two of them, atezolizumab and durvalumab, were first approved for the treatment of bladder cancer 59 (Table 1).